Effects of External Inspection on Sepsis Detection and Treatment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02747121 |
Recruitment Status :
Completed
First Posted : April 21, 2016
Results First Posted : March 24, 2022
Last Update Posted : March 24, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sepsis | Behavioral: External inspection of health services | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 7407 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Intervention Model Description: | The intervention will be rolled out sequentially during 12 months to 24 hospitals, with six clusters of four geographically close hospitals. We collect data before and after the inspections. |
Masking: | None (Open Label) |
Primary Purpose: | Health Services Research |
Official Title: | Effects of External Inspection on Sepsis Detection and Treatment |
Study Start Date : | April 2016 |
Actual Primary Completion Date : | December 2020 |
Actual Study Completion Date : | December 2020 |
Arm | Intervention/treatment |
---|---|
Control before intervention
External inspection of health services. The intervention is external inspection of sepsis detection and treatment. The intervention is delivered on the organizational Level. Patient are not assigned to the intervention. The intervention is rolled out sequentially to 24 hospitals. We collect data at base line, before the inspections and 8 and 14 month after the inspections. The first arm is the Control period before the inspections.
|
Behavioral: External inspection of health services
The intervention is external inspections of acute hospitals addressing early detection and treatment of sepsis. The intervention is delivered on an organizational level. Individuals are not assigned to an intervention. The investigator use data from individuals to assess if the organizational intervention affects care. Therefore the investigator argues that that the study is observational. The inspection will have two components, a system revision and a follow up audit with verification of patient records 8 months later. The inspection can be considered a complex intervention. The study does not intend to evaluate the individual effects of the different components of the inspection, rather the effect of the inspection as a whole. |
Experimental: Intervention
External inspection of health services. We compare the effect measures before and after the inspection. The intervention arm is data after the hospitals have received the inspection.
|
Behavioral: External inspection of health services
The intervention is external inspections of acute hospitals addressing early detection and treatment of sepsis. The intervention is delivered on an organizational level. Individuals are not assigned to an intervention. The investigator use data from individuals to assess if the organizational intervention affects care. Therefore the investigator argues that that the study is observational. The inspection will have two components, a system revision and a follow up audit with verification of patient records 8 months later. The inspection can be considered a complex intervention. The study does not intend to evaluate the individual effects of the different components of the inspection, rather the effect of the inspection as a whole. |
- Number of Sepsis Patients With 30 Days Mortality [ Time Frame: 30 days ]We will still use 30-day mortality rate as our outcome measure. The new international sepsis definition will over time affect coding practice and we can therefore not use routine data from the National Patient Register to calculate the mortality rate. We will calculate the mortality rate based on the patient population we include in the study. We will compare mortality rates before and after the inspections.
- Hospital Length of Stay [ Time Frame: Exact number of days for the length of stay was collected from the National Patient Registry. Since the outcome measure is length of stay, the time frame varies between patients. Time frame for observation periode was at least 12 months for each patient. ]Mean time for hospital length of stay before and after inspections

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Suspected infection and minimum 2 SIRS criteria. If high leucocytes are one of the two criteria, then 3 SIRS criteria are needed.
Exclusion Criteria:
- Patients below the age of 18 years.
- Patients who do not pass through the emergency room.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02747121
Norway | |
Haukeland hospital | |
Bergen, Hordaland, Norway, 5021 |
Study Chair: | Jan Fredrik Andresen, MD | Head of Norwegian Board of Health Supervision |
Documents provided by Norwegian Board of Health Supervision:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Norwegian Board of Health Supervision |
ClinicalTrials.gov Identifier: | NCT02747121 |
Other Study ID Numbers: |
2015/2195 REK number |
First Posted: | April 21, 2016 Key Record Dates |
Results First Posted: | March 24, 2022 |
Last Update Posted: | March 24, 2022 |
Last Verified: | January 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | In line with the ethical approval data is not to be shared outside the research group |
External inspections |
Sepsis Toxemia Infections |
Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes |